These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35611065)

  • 1. Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021-January 2022: A retrospective, population-based, matched cohort study.
    Auvigne V; Vaux S; Strat YL; Schaeffer J; Fournier L; Tamandjou C; Montagnat C; Coignard B; Levy-Bruhl D; Parent du Châtelet I
    EClinicalMedicine; 2022 Jun; 48():101455. PubMed ID: 35611065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads.
    Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH
    medRxiv; 2022 Jan; ():. PubMed ID: 35118480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Nationwide Cohort Study of Delta and Omicron SARS-CoV-2 Outcomes in Vaccinated Individuals With Chronic Lung Disease.
    Wee LE; Tan JYJ; Chiew CJ; Abisheganaden JA; Chotirmall SH; Lye DCB; Tan KB
    Chest; 2024 Oct; 166(4):685-696. PubMed ID: 38871281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study.
    Skarbinski J; Wood MS; Chervo TC; Schapiro JM; Elkin EP; Valice E; Amsden LB; Hsiao C; Quesenberry C; Corley DA; Kushi LH
    Lancet Reg Health Am; 2022 Aug; 12():100297. PubMed ID: 35756977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study.
    Krutikov M; Stirrup O; Nacer-Laidi H; Azmi B; Fuller C; Tut G; Palmer T; Shrotri M; Irwin-Singer A; Baynton V; Hayward A; Moss P; Copas A; Shallcross L;
    Lancet Healthy Longev; 2022 May; 3(5):e347-e355. PubMed ID: 35531432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in Chest CT Severity and Improved Hospital Outcomes in SARS-CoV-2 Omicron Compared with Delta Variant Infection.
    Tsakok MT; Watson RA; Saujani SJ; Kong M; Xie C; Peschl H; Wing L; MacLeod FK; Shine B; Talbot NP; Benamore RE; Eyre DW; Gleeson F
    Radiology; 2023 Jan; 306(1):261-269. PubMed ID: 35727150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
    Bohnert AS; Kumbier K; Rowneki M; Gupta A; Bajema K; Hynes DM; Viglianti E; O'Hare AM; Osborne T; Boyko EJ; Young-Xu Y; Iwashyna TJ; Maciejewski M; Schildhouse R; Dimcheff D; Ioannou GN
    BMJ; 2023 May; 381():e074521. PubMed ID: 37220941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Severity of COVID-19 Variants of Concern: Retrospective Population-Based Analysis.
    Harrigan SP; Velásquez García HA; Abdia Y; Wilton J; Prystajecky N; Tyson J; Fjell C; Hoang L; Kwong JC; Mishra S; Wang L; Sander B; Janjua NZ; Sbihi H
    JMIR Public Health Surveill; 2024 Aug; 10():e45513. PubMed ID: 39190434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study.
    Ward IL; Bermingham C; Ayoubkhani D; Gethings OJ; Pouwels KB; Yates T; Khunti K; Hippisley-Cox J; Banerjee A; Walker AS; Nafilyan V
    BMJ; 2022 Aug; 378():e070695. PubMed ID: 35918098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study.
    Lauring AS; Tenforde MW; Chappell JD; Gaglani M; Ginde AA; McNeal T; Ghamande S; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Halasa N; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Lindsell CJ; Hart KW; Zhu Y; Adams K; Schrag SJ; Olson SM; Kobayashi M; Verani JR; Patel MM; Self WH;
    medRxiv; 2022 Feb; ():. PubMed ID: 35169811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal and perinatal outcomes following pre-Delta, Delta, and Omicron SARS-CoV-2 variants infection among unvaccinated pregnant women in France and Switzerland: a prospective cohort study using the COVI-PREG registry.
    Favre G; Maisonneuve E; Pomar L; Daire C; Poncelet C; Quibel T; Monod C; Martinez de Tejada B; Schäffer L; Papadia A; Radan AP; Todesco-Bernasconi M; Ville Y; Voekt CA; Eggel-Hort B; Capoccia-Brugger R; Johann S; Grawe C; Defert S; Mottet N; Kahlert CR; Garabedian C; Sentilhes L; Weber B; Leu S; Bassler D; Lepigeon K; Winterfeld U; Panchaud A; Baud D;
    Lancet Reg Health Eur; 2023 Mar; 26():100569. PubMed ID: 36628358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.